Optimal left ventricular ejection fraction in risk stratification of patients with cardiac sarcoidosis.
Journal Information
Full Title: Europace
Abbreviation: Europace
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflicts of interest: Dr. Callahan is a consultant for Biotronik. Dr. Tang is a consultant for Sequana Medical A.V., Cardiol Therapeutics Inc., Genomics plc, Zehna Therapeutics LLC, and Renovacor Inc. and has received honorarium from Springer Nature for authorship/editorship and American Board of Internal Medicine for exam approval committee—all unrelated to the subject and contents of this paper. The remaining authors have nothing to disclose."
Funding Disclosure
Evidence found in paper:
"Funding No extramural funding was used to support this work."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025